Berlin - Delayed Quote EUR

Applied Therapeutics Inc (2UV.BE)

0.2958

+0.0332

+(12.64%)

At close: April 17 at 9:52:10 PM GMT+2

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results

- Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Quality NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter

GlobeNewswire 5 days ago

APLT
Russell 2000 Enters Bear Market With Small Caps Stung by Tariffs

(Bloomberg) -- The revival in small caps expected from Donald Trump’s America First agenda instead turned into a rout for shares in companies whose fortunes are most closely tied to the US economy.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersMetro-North Is Faster Than Acela on NYC-New Haven Route After Signal UpdatesLocal Governments Vie for Fired Federal WorkersLondon Clears Final Hurdle for More High-Speed Trains to EuropeWhat Would ‘Transportation Abundance’ Look

Bloomberg 16 days ago

ARHS

FWRD

SPCE
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company’s Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K

GlobeNewswire 19 days ago

APLT
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

Dr. Baumgartner will advance Applied’s preparation for upcoming regulatory interactionsNEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company’s executive leadership team and will be responsible for leading Applied’s global regulat

GlobeNewswire last month

APLT
3 Penny Stocks With At Least $50M Market Cap

The U.S. stock market has recently seen a rebound, buoyed by an encouraging Consumer Price Index report that suggests potential adjustments in Federal Reserve policies. For investors seeking opportunities beyond the well-known giants, penny stocks—typically smaller or newer companies—can present intriguing possibilities despite their somewhat outdated label. This article explores three penny stocks that showcase financial strength and potential for growth, offering investors a chance to...

Simply Wall St. last month

TOUR

APLT

HYLN
Why pharma is still far from a treatment for galactosemia

With issues in therapy delivery and a barren trial landscape, short-term chances for a commercial galactosemia treatment are low.

Clinical Trials Arena last month

APLT
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

BeiGene (ONC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks last month

ONC

APLT
Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

Ms. Colacot brings over 25 years of quality leadership experience across the biopharmaceutical and medical device industriesNEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmace

GlobeNewswire 2 months ago

APLT
Is Applied Therapeutics (APLT) the Best Penny Stock to Invest In According to Media?

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Applied Therapeutics, Inc. (NASDAQ:APLT) stands against other penny stocks to buy according to the media. Small-Cap Stocks Outlook for 2025 On December 24, Global Advisors’ […]

Insider Monkey 3 months ago

APLT

^RUT

^GSPC
Here’s Why Applied Therapeutics, Inc. (NASDAQ:APLT) Is Among the Best Diabetes Stocks to Buy Under $10

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where Applied Therapeutics, Inc. (NASDAQ:APLT) stands against the other diabetes stocks. Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration About 422 million […]

Insider Monkey 3 months ago

APLT
Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Adrian Alexandru, representing all similarly affected investors, has filed a federal securities class-action lawsuit against Applied Therapeutics (NASDAQ:APLT), alleging the company violated federal securities laws. The lawsuit claims that the company provided misleading information about its clinical trials and failed to disclose key adverse facts, causing significant financial losses for shareholders. Also Read: Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbust

Benzinga 3 months ago

APLT
Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr

GlobeNewswire 3 months ago

RVPH

RVPHW

VSTM
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 months ago

APLT
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says

Applied Therapeutics (APLT) faces uncertainty after the US Food and Drug Administration rejected the

PREMIUM
MT Newswires 4 months ago

APLT
Company News for Dec 2, 2024

Companies in The News Are: APLT,TGT,WMT,AAPL

Zacks 4 months ago

APLT

WMT

TGT
Applied Therapeutics CRL a ‘major setback,’ says William Blair

William Blair says Applied Therapeutics (APLT)’ complete response letter from the FDA for govorestat for the treatment of galactosemia is “unexpected and disappointing.” Given the lack of information in the CRL, it is unclear what the path forward for govorestat in galactosemia is and whether an additional clinical trial will be necessary for approval in this indication, the analyst tells investors in a research note. The firm says that while the rejection is a “major setback,” there is a possib

TipRanks 4 months ago

APLT
Applied Therapeutics downgraded to Sector Perform from Outperform at RBC

RBC Capital analyst Brian Abrahams downgraded Applied Therapeutics (APLT) to Sector Perform from Outperform with a price target of $4, down from $12. The complete response letter for govorestat in galactosemia is disappointing and “creates significant uncertainties” around a future path forward for the drug in that indication, the analyst tells investors in a research note. The firm still sees “meaningful residual value” from sorbitol dehydrogenase deficiency where a new drug application submiss

TipRanks 4 months ago

APLT
FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76%

The company plans to request a meeting with the FDA to discuss potential resubmission

GuruFocus.com 4 months ago

APLT
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

SAVA and APLT tank on pipeline and regulatory setbacks.

Zacks 4 months ago

BBIO

APLT

SAVAW
Top Midday Decliners

Applied Therapeutics (APLT) late Wednesday said the US Food and Drug Administration has issued a com

PREMIUM
MT Newswires 4 months ago

APLT

RMBL

Performance Overview

Return	2UV.BE	S&P 500 (^GSPC)
YTD	-63.57%	-10.18%
1-Year	-93.70%	+5.19%
3-Year	-84.50%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Applied Therapeutics Inc (2UV.BE)

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results

Russell 2000 Enters Bear Market With Small Caps Stung by Tariffs

Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

3 Penny Stocks With At Least $50M Market Cap

Why pharma is still far from a treatment for galactosemia

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

Is Applied Therapeutics (APLT) the Best Penny Stock to Invest In According to Media?

Here’s Why Applied Therapeutics, Inc. (NASDAQ:APLT) Is Among the Best Diabetes Stocks to Buy Under $10

Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says

Company News for Dec 2, 2024

Applied Therapeutics CRL a ‘major setback,’ says William Blair

Applied Therapeutics downgraded to Sector Perform from Outperform at RBC

FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76%

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

Top Midday Decliners

Performance Overview